Scholars Central

Research articlePublished 2013

Effect of Inhaled Corticosteroid Therapy Step-Down and Dosing Regimen on Measures of Asthma Control

Authors: David Price, Alison Chisholm, Elizabeth V Hillyer, Annie Burden, Julie von Ziegenweidt, Henrik Svedsater, Peter Dale

Journal of Allergy & Therapy

Volume 4 · Issue 1 · Pages 1–8

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Asthma guidelines recommend stepping down therapy to the lowest dose that maintains asthma control. Objective: We sought to evaluate the effect of dosing frequency and baseline patient and treatment-related factors on database markers of asthma control after inhaled corticosteroid (ICS) dose step-down. Methods: This retrospective observational study evaluated primary care patients (4-80 years old) with asthma prescribed twice-daily (BD) ICS (n=26,834) or ICS/long-acting β-agonist (LABA; n=20,814) for ≥ 1 year before ≥ 50% step-down in ICS dose, when they were switched to once-daily (QD) or remained on BD therapy. Study endpoints included exacerbations (oral corticosteroid prescription, unscheduled asthma-related hospital attendance, or general practice consultation for lower respiratory tract infection) and medication adherence. Results: Significant improvements in most endpoints were recorded during the year after step-down, as compared with the prior year (baseline). The proportion of patients with no exacerbation during the baseline year vs. the year after step-down was as follows (p<0.001 for all comparisons): QD ICS cohort (73% baseline vs. 81% after step-down); BD ICS cohort (67% vs. 77%); QD ICS/LABA cohort (60% vs. 64%); BD ICS/LABA cohort (55% vs. 65%). Adherence improved significantly after step-down for all cohorts, most markedly for QD cohorts; and the average daily ICS dose as consumed by patients was higher for all but the QD ICS/LABA cohort despite the reduction in prescribed dose. Factors predicting loss of asthma control after step-down for patients controlled at baseline in either or both ICS and ICS/LABA populations included obesity, smoking, comorbid rhinitis, comorbid gastroesophageal reflux disease, and, during the baseline year, ≥ 7 short-acting β-agonist prescriptions, mean consumed ICS dose of ≥ 800 μg/day, and ≥ 4 primary care consultations. Conclusion: Stepping down therapy is a valid management option and may improve asthma-related outcomes. Some improvements may result from increased adherence, particularly among patients switched to QD therapy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Allergy & Therapy
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “David Price”
  • BylineArticles whose byline prints “Alison Chisholm”
  • BylineArticles whose byline prints “Elizabeth V Hillyer”
  • BylineArticles whose byline prints “Annie Burden”
  • BylineArticles whose byline prints “Julie von Ziegenweidt”
  • BylineArticles whose byline prints “Henrik Svedsater”
  • BylineArticles whose byline prints “Peter Dale”